Progression time of de novo metastases in relation to castration resistant prostate cancer at a tertiary care hospital in Southern Thailand

Authors

  • Nawaporn Kittaweerat Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
  • Virote Chalieopanyarwong Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
  • Worapat Attawettayanon Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
  • Choosak Pripatnanont Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
  • Thanyalak Samphantharat Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
  • Tanan Bejrananda Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand
  • Monthira Tanthanuch Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand

DOI:

https://doi.org/10.52786/isu.a.51

Keywords:

Metastasis prostate cancer, androgen deprivation therapy, orchiectomy, castration-resistant prostate cancer, high volume metastatic prostate cancer

Abstract

Objective: Androgen deprivation therapy (ADT) is often the treatment of choice in metastatic prostate cancer patients. However, there is currently an insufficiency of biomarker-related data that can be used in order to predict how the disease would respond to ADT. In this study we evaluated the clinical response to ADT, including factors which are affecting the progression of the disease into castration-resistant prostate cancer (CRPC) in patients with de novo metastatic prostate cancer.

Materials and Methods: This retrospective study incorporated patients with metastatic prostate cancer who received ADT at our center from January 2008 to December 2019. Baseline characteristics, mode of ADT, prostate-specific antigen (PSA), blood chemistry, Gleason score (GS) grade group, location, and the number of metastases were analyzed. The risk factors affecting the progression of the disease were identified.

Results: Data from 125 patients were included in the study. One hundred patients (80%) were classified as suffering from high volume metastatic prostate cancer and six patients (6%) with visceral metastasis. Baseline PSA in high volume and low volume metastatic prostate cancer were defined as 500 ng/ml and 215.1 ng/ ml respectively. Eighty-one patients (64.8%) received a gonadotrophin-releasing hormone (GnRH) agonist while 42 patients (33.6%) underwent bilateral orchi- ectomy. Time to CRPC in high and low volume metastasis was 12 months and 23 months respectively. Patients with Alkaline Phosphatase (ALP) ≥350 U/L had 8.5 months to CRPC while patients with ALP <350 U/L had 15 months. High GS grade group (3-5), short time to PSA nadir (<6 months), PSA nadir level (≥ 2 ng/ ml), and serum ALP ≥350 U/L were independent factors associated with shorter time to CRPC.

Conclusion: The clinical management of metastatic prostate cancer is challenging; the main aims of treatment are to prolong overall survival whilst maintaining quality of life. Patients with aggressive tumors, high volume metastasis, short time to nadir (TTN), high PSA nadir level, and high ALP level were independent factors associated with shorter time to CRPC.

Downloads

Download data is not yet available.

References

Lojanapiwat B. Urologic cancer in Thailand. Jpn J Clin Oncol 2015;45:1007e15.

Tantiwong A, Soontrapa S, Sujijantrarat P, Vanprapar N, Sawangsak L. The prevalence of prostate cancer screening in Thai elderly. J Med Assoc Thai 2002; 85:502e8.

Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, et al. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel) 2019;11:1355.

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080-87.

Tamada S, Iguchi T, Kato M, Asakawa J, Kita K, Yasuda S, et al. Time to progression to castrationresistant prostate cancer after commencing combined androgen blockade for advanced hormonesensitive prostate cancer. Oncotarget 2018;9:36966-74.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic HormoneSensitive Prostate Cancer. N Engl J Med 2015;373:737-46.

Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, et al. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Sci Rep 2019;9:12071:48600-8.

Watanabe M, Kanao K, Sugie M, Morinaga S, Mu- ramatsu H, Kobayashi I, et al. Prognostic and predictive clinical factors for progression to castration refractory prostate cancer in patients with hormone sensitive prostate cancer. Ann Oncol 2018;29:IX73.

Lin T, Chen YH, Wu YP, Chen SZ, Li XD, Lin YZ, et al. Risk factors for progression to castrationresistant prostate cancer in metastatic prostate cancer patients. J Cancer 2019;10:5608-13.

Kongseang C, Attawettayanon W, Kanchanawanichkul W, Pripatnanont C. Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer. Prostate Int 2017;35-8.

Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J. Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e2544.

Wang J, Zhou X, He Y, Chen X, Liu N, Ding Z, et al. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Medicine (Baltimore) 2018;97:e12504.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors, special article. J Nat Cancer Inst 2000;92:205-16.

Hashmi AA, Mudassir G, Irfan M, Hussain ZF, Hashmi SK, Asif H, et al. Prognostic significance of high androgen receptor expression in prostate acinar adenocarcinoma. Asian Pac J Cancer Prev 2019;20:893-6.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, et al. Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer. Eur Urol 2019;75:35-41.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:686-700.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Hol- zbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2019;37:2974-86.

Wenzel M, Preisser F, Hoeh B, Schroeder M, Würnschimmel C, Steuber T, et al. Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies. Front Oncol 2021; 11:659135.

Narita T, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, et al. Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis. Transl Androl Urol 2021;10:417-25.

Filella X, Fernandez-Galan E, Fernandez Bonifacio R, Foj L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med 2018;11: 83-94.

Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20:12-9.

Choueiri TK, Xie W, D’Amico AV, Ross RW, Hu JC, Pomerantz M, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009;115:981-7.

Hamano I, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, et al. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol 2019;37:2365-73.

Sasaki T, Onishi T, and Hoshina A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 2011;14:248-52.

Lin YC, Lin PH, Shao IH, Chu YC, Kan HC, Liu CY, et al. Prostate-specific antigen kinetics effects on outcomes of low-volume metastatic prostate cancer patients receiving androgen deprivation therapy. J Oncol 2021;2021:9648579.

Lin TT, Chen YH, Wu YP, Chen SZ, Li XD, Lin YZ, et al. Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients. J Cancer 2019;10:5608-13.

Tamada S, Iguchi T, Kato M, Asakawa J, Kita K, Yasuda S, et al. Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget 2018;9:36966-74.

Hammerich KH, Donahue TF, Rosner IL, Cullen J, Kuo HC, Hurwitz L, et al. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Urol Oncol 2017;35:460.e21-8.

Mikah P, Krabbe LM, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, et al. Dynamic changes of alkaline phosphatase are strongly asso- ciated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer 2016;16:214.

Downloads

Published

2022-06-17

How to Cite

Kittaweerat, N., Chalieopanyarwong, V., Attawettayanon, W., Pripatnanont, C. ., Samphantharat, T., Bejrananda, T. ., & Tanthanuch, M. . (2022). Progression time of de novo metastases in relation to castration resistant prostate cancer at a tertiary care hospital in Southern Thailand. Insight Urology, 43(1), 75–83. https://doi.org/10.52786/isu.a.51

Issue

Section

Original article

Most read articles by the same author(s)

> >>